Nat. Med. 9, 589–595 (2003)

In response to a query on the limitations of presenting changes in drug treatment as percentage changes in levodopa equivalents, as shown in Table 1 of our article, we would like to submit further supplementary information detailing the actual drug changes during the course of this phase 1 clinical study. This information would allow for a better clinical interpretation of the participants, who showed both significant off- and on-medication benefit. Accordingly, we have tabulated the drug and levodopa equivalent changes up to 24 months, beyond the 12-month clinical data and 18-month positron emission tomography data presented in our article.

Table 1
Full size table